Welcome from Prof Matthew Wood
The laboratory works at the interface of neuromuscular science and biotechnology. A major focus is the study of neuromuscular diseases such as Duchenne muscular dystrophy, myotonic dystrophy and spinal muscular atrophy and the development of gene-based therapies, in particular RNA-based therapies, for this class of disorders. A central challenge in our work is the effective delivery of such therapies to the target tissues of skeletal muscle, heart and nervous system. To address this the team has pioneered the development of numerous delivery technologies ranging from peptide to antibody to nanotechnologies based on natural nanoparticles known as exosomes. Our goal is to advance the science underlying these innovative therapies to develop the truly innovative precision medicines of the future and to advance their translation to the benefit of patients.
Please join our efforts!